Autres langues Rani Therapeutics Holdings, Inc.

Actions

RANI

US7530181004

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,8108 ^USD	+1,92%		+6,80%	-39,94%

18/08	Rani Therapeutics Holdings, Inc. : Opinion positive de Chardan Research	ZM
13/08	Rani Therapeutics Holdings, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

08/09	Rani Therapeutics to Participate in Upcoming September Conferences
13/08	Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
10/08	Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
04/08	Rani Therapeutics Holdings, Inc. Appoints Michelle Gilson as Director and Chair of the Audit Committee, Effective August 1, 2026
04/08	Rani Therapeutics Appoints Michelle Gilson to Board of Directors
20/07	Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15/07	Rani Therapeutics Reports Positive Initial Phase 1A Data for Rt-114 for the Treatment of Obesity
15/07	Rani Therapeutics Reports Positive Initial Phase 1a Data for RT-114 in Obesity
15/07	Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
10/07	PegBio Signs MoU with Rani Therapeutics to Develop Metabolic Therapies; Shares Jump 35%
09/07	Rani Therapeutics Holdings, Inc. and Pegbio Co., Ltd. Announce Research and Development Collaboration to Expand Obesity Pipeline Across Multiple Novel Candidates
09/07	Rani Therapeutics, PegBio Collaborate on Oral Delivery of Obesity Drugs
09/07	Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
29/06	Rani Therapeutics Holdings, Inc. Announces Appointment of Nicholas Maestas as Chief Financial Officer, Effective June 29, 2026
29/06	Rani Therapeutics Names Nicholas Maestas CFO
29/06	Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
26/05	Rani Therapeutics Prices Registered Direct Offering of 12.5 Million Shares
26/05	Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
15/05	Rani Therapeutics Q1 Net Loss Narrows, Revenue Rises; CFO Svai Sanford to Step Down
15/05	Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/05	Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
15/05	Rani Therapeutics Holdings, Inc. Announces Svai Sanford Will Transition from the Role of Chief Financial Officer
12/05	Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
09/04	Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy